4.8 Article

Missense Mutations and Single Nucleotide Polymorphisms in ABCB11 Impair Bile Salt Export Pump Processing and Function or Disrupt Pre-Messenger RNA Splicing

期刊

HEPATOLOGY
卷 49, 期 2, 页码 553-567

出版社

WILEY
DOI: 10.1002/hep.22683

关键词

-

资金

  1. Guy and St Thomas' Charity, London, UK
  2. Associazione Ricercaperil Canto
  3. Medical Research Council [MC_U120088463] Funding Source: researchfish
  4. MRC [MC_U120088463] Funding Source: UKRI

向作者/读者索取更多资源

The gene encoding the human bile salt export pump (BSEP), ABCB11, is mutated in several forms of intrahepatic cholestasis. Here we classified the majority (63) of known ABCB11 missense mutations and 21 single-nucleotide polymorphisms (SNPs) to determine whether they caused abnormal ABCB11 pre-messenger RNA splicing, abnormal processing of BSEP protein, or alterations in BSEP protein function. Using an in vitro minigene system to analyze splicing events, we found reduced wild-type splicing for 20 mutations/SNPs, with normal mRNA levels reduced to 5% or less in eight cases. The common ABCB11 missense mutation encoding D482G enhanced aberrant splicing, whereas the common SNP A1028A promoted exon skipping. Addition of exogenous splicing factors modulated several splicing defects. Of the mutants expressed in vitro in CHO-K1 cells, most appeared to be retained in the endoplasmic reticulum and degraded. A minority had BSEP levels similar to wild-type. The SNP variant A444 had reduced levels of protein compared with V444. Treatment with glycerol and incubation at reduced temperature overcame processing defects for several mutants, including E297G. Taurocholate transport by two assessed mutants, N490D and A570T, was reduced compared with wild-type. Conclusion: This work is a comprehensive analysis of 80% of ABCB11 Missense mutations and single-nudeotide polymorphisms at pre-mRNA splicing and protein processing/functional levels. We show that aberrant pre-mRNA splicing occurs in a considerable number of cases, leading to reduced levels of normal mRNA. Thus, primary defects at either the protein or the mRNA level (or both) contribute significantly to BSEP deficiency. These results will help to develop mutation-specific therapies for children and adults suffering from intrahepatic cholestasis due to BSEP deficiency. (HEPATOLOGY 2009;49:553-567.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Allergy

Autoimmune Hepatitis: Serum Autoantibodies in Clinical Practice

Benedetta Terziroli Beretta-Piccoli, Giorgina Mieli-Vergani, Diego Vergani

Summary: Circulating autoantibodies are crucial for the diagnosis and classification of autoimmune hepatitis (AIH). The reference method for autoantibody testing remains indirect immunofluorescence, despite limitations. Further studies are needed to validate automated assays as reliable alternatives.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2022)

Review Gastroenterology & Hepatology

Cutting edge issues in juvenile sclerosing cholangitis

Angelo Di Giorgio, Diego Vergani, Giorgina Mieli-Vergani

Summary: Sclerosing cholangitis is a rare chronic disorder characterized by inflammation and progressive fibrosis of the bile ducts. The most common form in children is associated with autoimmune features and inflammatory bowel disease. The disease can progress to biliary cirrhosis and end-stage liver disease, potentially requiring liver transplantation.

DIGESTIVE AND LIVER DISEASE (2022)

Letter Pediatrics

Does early diagnosis and management improve liver-related outcomes in children with inflammatory bowel disease and sclerosing cholangitis? Reply

Marianne Samyn, Kai Hensel, Nedim Hadzic, Giorgina Mieli-Vergani

JOURNAL OF PEDIATRICS (2022)

Review Immunology

Autoimmmune hepatitis

Benedetta Terziroli Beretta-Piccoli, Giorgina Mieli-Vergani, Diego Vergani

Summary: Autoimmune hepatitis is an inflammatory liver disease affecting all ages, with type 1 and type 2 having different autoantibodies and predisposing factors, typically responding well to treatment with steroids and azathioprine.

CELLULAR & MOLECULAR IMMUNOLOGY (2022)

Article Gastroenterology & Hepatology

Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis

Jonathon J. Graham, Sujit Mukherjee, Muhammad Yuksel, Rebeca Sanabria Mateos, Tengfei Si, Zhenlin Huang, Xiahong Huang, Hadil Abu Arqoub, Vishal Patel, Mark McPhail, Yoh Zen, Nigel Heaton, Maria Serena Longhi, Michael A. Heneghan, Rodrigo Liberal, Diego Vergani, Giorgina Mieli-Vergani, Yun Ma, Bu'Hussain Hayee

Summary: The study found that the gut homing hypothesis is not the primary driver of PSC, and aberrant recruitment of gut-derived T cells to the liver is also seen in other chronic liver diseases. This finding provides a new understanding of the pathogenesis of PSC and CLD.

HEPATOLOGY (2022)

Review Gastroenterology & Hepatology

Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group

Simon Pape, Romee J. A. L. M. Snijders, Tom J. G. Gevers, Oliver Chazouilleres, George N. Dalekos, Gideon M. Hirschfield, Marco Lenzi, Michael Trauner, Michael R. Manns, John M. Vierling, Aldo J. Montano-Loza, Ansgar W. Lohse, Christoph Schramm, Joost P. H. Drenth, Michael A. Heneghan

Summary: The International Autoimmune Hepatitis Group proposed a consensus on response criteria and endpoints in autoimmune hepatitis, defining terms like complete biochemical response, insufficient response, non-response, remission, and intolerance to treatment to guide future reporting.

JOURNAL OF HEPATOLOGY (2022)

Editorial Material Gastroenterology & Hepatology

Reassessement of the histological features of autoimmune hepatitis

Giorgina Mieli-Vergani, Yoh Zen, Diego Vergani

LIVER INTERNATIONAL (2022)

Article Genetics & Heredity

Rescue of a familial dysautonomia mouse model by AAV9-Exon-specific U1 snRNA

Giulia Romano, Federico Riccardi, Erica Bussani, Simone Vodret, Danilo Licastro, Isabella Ragone, Giuseppe Ronzitti, Elisabetta Morini, Susan A. Slaugenhaupt, Franco Pagani

Summary: This study successfully delivered ExSpeU1 small nuclear RNA using AAV9-U1-FD vector in a mouse model of FD, which increased the inclusion of ELP1 exon 20 and production of functional protein. The treatment rescued the majority of FD mouse mortality and improved motor function, renal function, and cardiac function. RNA-seq analysis showed minimal global changes in gene expression and splicing. This therapeutic strategy shows high specificity and potential for treating FD.

AMERICAN JOURNAL OF HUMAN GENETICS (2022)

Article Gastroenterology & Hepatology

ATP7B Genotype and Chronic Liver Disease Treatment Outcomes in Wilson Disease: Worse Survival With Loss-of- Function Variants

Jeremy S. Nayagam, Rebecca Jeyaraj, Pierre Foskett, Anil Dhawan, Aftab Ala, Deepak Joshi, Adrian Bomford, Richard J. Thompson

Summary: This study retrospectively reviewed 117 patients with hepatic Wilson disease, and found that patients with LOF variants in the ATP7B gene have a worse prognosis during long-term treatment. Close monitoring is recommended for this subgroup of patients to ensure early detection and management of disease progression.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial

Richard J. Thompson, Henrik Arnell, Reha Artan, Ulrich Baumann, Pier Luigi Calvo, Piotr Czubkowski, Buket Dalgic, Lorenzo D'Antiga, Ozlem Durmaz, Bjorn Fischler, Emmanuel Gonzales, Tassos Grammatikopoulos, Girish Gupte, Winita Hardikar, Roderick H. J. Houwen, Binita M. Kamath, Saul J. Karpen, Lise Kjems, Florence Lacaille, Alain Lachaux, Elke Lainka, Cara L. Mack, Jan P. Mattsson, Patrick McKiernan, Hasan Ozen, Sanjay R. Rajwal, Bertrand Roquelaure, Mohammad Shagrani, Eyal Shteyer, Nisreen Soufi, Ekkehard Sturm, Mary Elizabeth Tessier, Henkjan J. Verkade, Patrick Horn

Summary: The study evaluated the effects of odevixibat, an ileal bile acid transporter inhibitor, versus placebo in children with PFIC. The results showed that odevixibat effectively reduced pruritus and serum bile acids compared to placebo, and it was generally well-tolerated.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor

Ronald J. Sokol, Emmanuel M. Gonzales, Binita M. Kamath, Alastair Baker, Pamela Vig, Douglas B. Mogul, Will Garner, Bettina E. Hansen, Emmanuel Jacquemin, Richard J. Thompson

Summary: Improvement in pruritus by 48 weeks, and lower W48 bilirubin and serum bile acid levels were associated with fewer events in patients with Alagille syndrome (ALGS) treated with maralixibat (MRX).

HEPATOLOGY (2023)

Editorial Material Gastroenterology & Hepatology

Choluresis?

Richard J. Thompson

HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency

Antonia Felzen, Daan B. E. van Wessel, Emmanuel Gonzales, Richard J. Thompson, Irena Jankowska, Benjamin L. Shneider, Etienne Sokal, Tassos Grammatikopoulos, Agustina Kadaristiana, Emmanuel Jacquemin, Anne Spraul, Patryk Lipinski, Piotr Czubkowski, Nathalie Rock, Mohammad Shagrani, Dieter Broering, Emanuele Nicastro, Deirdre Kelly, Gabriella Nebbia, Henrik Arnell, Bjoern Fischler, Jan B. F. Hulscher, Daniele Serranti, Cigdem Arikan, Esra Polat, Dominique Debray, Florence Lacaille, Cristina Goncalves, Loreto Hierro, Gema Munoz Bartolo, Yael Mozer-Glassberg, Amer Azaz, Jernej Brecelj, Antal Dezsofi, Pier Luigi Calvo, Enke Grabhorn, Steffen Hartleif, Wendy J. van der Woerd, Binita M. Kamath, Jian-She Wang, Liting Li, Ozlem Durmaz, Nanda Kerkar, Marianne Horby Jorgensen, Ryan Fischer, Carolina Jimenez-Rivera, Seema Alam, Mara Cananzi, Noemie Laverdure, Cristina Targa Ferreira, Felipe Ordonez Guerrero, Heng Wang, Valerie Sency, Kyung Mo Kim, Huey-Ling Chen, Elisa de Carvalho, Alexandre Fabre, Jesus Quintero Bernabeu, Aglaia Zellos, Estella M. Alonso, Ronald J. Sokol, Frederick J. Suchy, Kathleen M. Loomes, Patrick J. McKiernan, Philip Rosenthal, Yumirle Turmelle, Simon Horslen, Kathleen Schwarz, Jorge A. Bezerra, Kasper Wang, Bettina E. Hansen, Henkjan J. Verkade

Summary: This study aimed to evaluate the relationship between genetic mutations related to BSEP deficiency and clinical features. The results showed that the combination of one relatively mild mutation and one severe mutation resulted in a clinical presentation similar to patients with two severe mutations, and they had a poor response to surgical interruption of the enterohepatic circulation.

JHEP REPORTS (2023)

Article Gastroenterology & Hepatology

Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis

Richard J. Thompson, Reha Artan, Ulrich Baumann, Pier Luigi Calvo, Piotr Czubkowski, Buket Dalgic, Lorenzo D'Antiga, Angelo Di Giorgio, Ozlem Durmaz, Emmanuel Gonzales, Tassos Grammatikopoulos, Girish Gupte, Winita Hardikar, Roderick H. J. Houwen, Binita M. Kamath, Saul J. Karpen, Florence Lacaille, Alain Lachaux, Elke Lainka, Kathleen M. Loomes, Cara L. Mack, Jan P. Mattsson, Patrick Mckiernan, Quanhong Ni, Hasan Ozen, Sanjay R. Rajwal, Bertrand Roquelaure, Eyal Shteyer, Etienne Sokal, Ronald J. Sokol, Nisreen Soufi, Ekkehard Sturm, Mary Elizabeth Tessier, Wendy L. van der Woerd, Henkjan J. Verkade, Jennifer M. Vittorio, Terese Wallefors, Natalie Warholic, Qifeng Yu, Patrick Horn, Lise Kjems

Summary: The ongoing PEDFIC 2 study evaluated the effectiveness of odevixibat in patients with progressive familial intrahepatic cholestasis. The study found that odevixibat can reduce serum bile acids and alleviate pruritus symptoms. This suggests that odevixibat may be a safe and effective treatment option for patients with progressive familial intrahepatic cholestasis.

JHEP REPORTS (2023)

Article Gastroenterology & Hepatology

Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1

Jeremy S. Nayagam, Pierre Foskett, Sandra Strautnieks, Kosh Agarwal, Rosa Miquel, Deepak Joshi, Richard J. Thompson

Summary: This study aims to investigate the variants in ATP8B1, ABCB11, and ABCB4 genes in adult-onset liver disease patients and explore the correlation between genotype and phenotype. The results show that these variants are frequently identified in patients with cholestasis and are likely to contribute to the development of liver disease. ABCB4 and ABCB11 variants are associated with chronic liver disease and pregnancy-associated liver dysfunction.

HEPATOLOGY COMMUNICATIONS (2022)

暂无数据